IFRX InflaRx N.V.

$IFRX 147.4M shares outstanding ~ $6.78 per share at $ 1B valuation $13.56 per share at $ 2B valuation $20.35 per share at $ 3B valuation Let's see at least $20+ this year, with 75% insitutional ownership. Partnership now! Neils you can do this!!! Kindest regards to all!

1/3 $IFRX CMD Nov 3: what could a best-case AAV design look like? My read of Niels' recent talks (my interpretation, not company guidance). Study: randomized, controlled Ph2b, ideally with blinded BVAS adjudication, first sites early 2027. BVAS is partly subjective (residual symptoms after 3 months), so blinding/adjudication matters a lot for credibility. Primary endpoint: BVAS 0 remission (wk 26) as NON-INFERIORITY vs standard of care. Why: sustained remission at wk 52 can't exceed the wk 26 rate (~70%). Control ~60% vs an ideal drug ~70% = 10 pts max. By his math that needs ~1,000 pts for superiority. NI with an FDA-accepted margin is far smaller.

$IFRX AAV: Innate Immunity and Kidney Damage An overview published online on October 23, 2026, in Autoimmunity Reviews summarizes evidence on the role of neutrophils, NETs and macrophages in ANCA-associated glomerulonephritis. It highlights C5a as an amplifier of neutrophil activation and inflammatory tissue damage. For IFRX, the paper provides mechanistic context: izicopan blocks C5aR1, while vilobelimab binds directly to C5a. The review contains no new clinical data on izicopan. Its value lies in bringing together a broad body of research into an updated overview; the literature search was updated in June 2026. - Original article: The role of innate immunity in disease initiation and damage control in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis DOI: 10.1016/j.autrev.2026.104200

$IFRX Nine years ago this upcoming week, Inflarx went public with their IPO at $15/share. Now it’s $1.66. On Tuesday, CMD needs to deliver a very positive, detailed and convincing strategy with strong data to generate a meaningful market cap rally. No pressure after nine years, multiple dilutions and several high profile trial failures.

$IFRX - sorry, but too many comments here are fueled by assumptions, if you don't like management, well sell and move on and stop blaming others for your shitty investment decisions. If I don't like something, I don't buy--period ... Last week and especially Friday was a correctional bear market without buyers, makes for a perfect opportunity for Institutions to cover their short position if needed when you consider IFRX is nearing an important event. Friday's available shares to short was 1.2 mil and today it's at 4.5 mil, so if you look at OBV which hasn't declined much, I'd say MM/Specialist are building their inventory heading to Nov event. The volume throughout the last month was mostly below average, just retail playing in between the bid and the ask to accommodate the MM/Specialist.... That's my take, and like the last post "Nov 3rd will reveal the truth, win or lose..." If OBV dropped considerably, I'd say something is seriously wrong, but that's not the case here.

$IFRX Kidney Week 2026 Late-Breaking Poster Details Title: Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models. Poster Session Session Title: Late-Breaking Research Posters [LB-PO] Session Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM Isn’t this something to be excited about?

$IFRX 🚀 Greetings from the astronaut of the wonderful land of potato pancakes! 🥔😄 Whether a piece of news puts pressure on the stock or sends it higher is beside the point. What matters is that the price reflects the relevant data and the situation at hand. But seriously, do we really think we'd dislike each other this much in real life? Do we really need to use our disappointment or excitement to throw the worst accusations about each other's character around? Come on, folks, let's keep it cool. We're all getting tossed around enough by every new headline as it is. 😅 There are much more interesting things to discuss: What initial data can we expect once Phase 2 gets underway, and what will the actual results tell us? We don't have to agree with each other to treat each other with respect. Greetings from your astronaut! 🚀🥔

$IFRX - OBV just spiked upward on 2.8 mil volume, eager to see what's fueling it ... Analysis paralysis in many ways is the beast of burden in trading stocks independently; it's the overwhelming need to find the many reasons on why not to buy it and the incessant need to keep revisiting those reasons even though you BOUGHT it... been doing this shit too long, and to quote a great philosopher, simplicity is man's last lesson. Love one woman, one career, the world one way, etc... in stocks, same shxt applies ... be more like a dog. When a dog looks in the mirror, the dogs sees a dog. Unfortunately, when humans look in the mirror, they change their mind everyday about what they see, hence, analysis paralysis ... Hopefully I'll make good money owning IFRX, I like the pipeline and its progress, institutional ownership, the chart, and many informative comments on this board therefor I'm in until Nov 3rd and that date will tell me to keep holding or move on. GLTA ☮️

$IFRX Given that CSL already has the established commercial relationships, sales force, and medical infrastructure for AAV in Europe via its Vifor division, onboarding IFRX's pipeline would allow CSL to salvage its European AAV footprint while creating perfect clinical synergy with its new Alentis asset.

$IFRX - Friday’s volume was average, but the difference, it made some indicators curl upward, especially RSI and OBV which means, mostly buyers, veryy similar to last 2 bottoms … still waiting for the price to close above the 8 DMA ☮️

$IFRX A new systematic review identifies aHUS/TMA in the pregnancy/postpartum context as a complement-mediated, renal-dominant condition and places complement biomarkers and complement-directed therapy within the diagnostic/therapeutic framework. Relevant to IFRX through the aHUS/complement connection to the Izicopan renal strategy. 30.09.2026 DOI: 10.4103/ijh.ijh_85_26 *Please verify the sources and content yourself.

$IFRX I was still expecting to see some anticipation buying / accumulation ahead of November 3rd… I already thought the stock was significantly undervalued at $2.50, and here we are still sitting at $1.50 just one week before an event that is « supposed » to be a major catalyst. This event was announced back in January, postponed several times, and hinges on FDA feedback that could be decisive for the future of the company. Anyway… nothing left to do but wait. One more week and we’ll see.

$IFRX CEO Niels Riedemann has been at the helm since 2007 (nearly 20 years) yet still hasn't secured a major big pharma partnership. The 2020 COVID pandemic was his ultimate missed opportunity. While the science behind vilobelimab (Gohibic) was solid, sluggish trial execution and late regulatory approvals meant missing the commercial wave completely. With the 2025 PG phase 3 failure added to the track record, long-term leadership remains a major question mark.

$IFRX My biggest interest is not whether IFRX loses 7 or 15 cents. It's whether the November 3 presentation establishes a credible path toward commercial revenue.

$IFRX Hope Niels keeps it tight this time 🙂Seems like the stock dips every time he speaks. Jokes aside, the PR is informative but neutral, with cautious wording. It confirms the Nov 3 format (KOLs, izicopan's differentiation, "anticipated" AAV program) but says nothing on FDA feedback, a partner or financing. A company wouldn't tease that kind of news anyway, so I wouldn't read too much into the silence either way.

$IFRX I want to walk back some of my recent comments. I don’t like InflaRx’s management, I don’t like the way they communicate, and I don’t like how they seem to disregard retail investors. All biotech companies prioritize long-term institutional investors to some extent, but with InflaRx, it’s particularly blatant. That said, the biotech sector is struggling badly right now, and pre-revenue companies like InflaRx are getting hit the hardest. The current environment also means the market could be even less forgiving than usual if the CMD disappoints (e.g. no accelerated pathway for AAV). I’ll wait and see how management executes before unleashing all my criticism (or not). We’ll know soon enough now.

$IFRX We need a partnership announcement to get us higher. We've been told for 4 years there have been talks but nothing has materialized. CMD will not be a huge catalyst in itself. I don't know how the analysts got this so wrong - for years and years.

$IFRX More of the same from this company. Been down this road multiple times before watching the market cap evaporate into thin air. Meanwhile, the silence from management is deafening 🫠

$IFRX We've come down to the levels that I had been expecting and suggesting for some time. This is pretty strong support zone and we're looking oversold, but I would not rule out continued downside. I remain bullish long term, however given recent market developments & timelines, I have downgraded my own internal thesis a bit. I no longer view a partnership on HS/CSU as plausible. PG is dead. ARDS still a possible tail success but JB trial site activation momentum has seemingly stalled and we're like years away from a readout. Izi/Vilo still look strongly positioned on AAV. An expedited trial protocol would be a nice upside suprise. The eventual renal data could also open up more opporuntities, but until see see in human data I'd assign zero value there. I know they are working as expediently as they can but highly disappointed from an execution standpoint. I'm sure we'll bounce back; but when?

$IFRX this management is awful. How have we not secured a partnership by now? What are these bozos doing on a daily basis? There seems to be zero drive to do anything with such a promising molecule!!